This KIR3DL1 antibody is conjugated to PerCP-Cy5.5
Application
Flow Cytometry (FACS)
Purification
The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.
KIR3DL1 antibody, KIR3DL3 antibody, CD158E1 antibody, KIR antibody, KIR3DL1/S1 antibody, NKAT3 antibody, NKB1 antibody, NKB1B antibody, Kirl1 antibody, Kirl2 antibody, Krl1 antibody, killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 antibody, uncharacterized LOC100437736 antibody, killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 antibody, KIR3DL1 antibody, LOC100437736 antibody, Kir3dl1 antibody
Background
CD158e1, also known as NKB1, is a 70 kD member of the immunoglobulin superfamily that is expressed on a subset of natural killer cells and T cells at varying levels among individuals. NKB1 is a type I membrane protein containing two immunoglobulin C2-type domains. The interaction of NKB1 with specific HLA-B antigens on a target cell (the HLA-Bw4 allele, for example) inhibits cytotoxicity and prevents target cell lysis and death. The interactions between KIR and MHC class I are thought to be important in NK and T cell regulation following antigen stimulation. The absence of ligands for KIRs may lower the threshold for activation through activating receptors and increase inflammation and susceptibility to autoimmune disease.